“Tegoprazan offers an exciting new treatment option for individuals suffering from GERD, helping to address the substantial unmet need of patients not well-controlled by conventional PPI therapy,” ...

Patients with GERD are usually treated with once-daily PPIs; however, studies have shown that 25–42% of patients treated with a standard-dose PPI continue to experience symptoms of GERD ...

GERD can be excluded by a negative pH study following failure of a PPI trial. Although new imaging technologies hold much promise, their role in GERD diagnosis in Asia still remains to be defined.